Become a member
bannière biohub 2100x452

Welcome to the MabDesign Bio-hub

On MabDesign’s Bio-Hub, you’ll find a wealth of content dedicated to the biopharmaceutical sector: themed market analyses, in-depth articles on biopharmaceuticals, bioproduction and all related technologies, not to mention our must-read ImmunoWatch and BioprocessWatch.

As a committed player in the biopharmaceutical industry, MabDesign channels its expertise into driving innovation and supporting the companies behind it. To find out more about our mission and our activities, please visit our ‘About Us’ page.

All themes
Tags
culture cellulaire

The beginnings of cell culture

Cell culture is the cornerstone of biomedical research and biotechnology innovation. Although the bioproduction of biomedicines in bioreactors is now the norm, and the use of organoids and "organ-on-a-chip" (OoC) is growing, the beginnings of in vitro cell culture were more modest.
marché glioblastome

Glioblastoma

This month's MabDesign market analysis gives you an overview of market dynamics and pipeline projects targeting the glioblastoma.
exosomes ; vésicules extracellulaires

Exosomes and extracellular vesicles

Long considered as cellular debris with no biological function, exosomes, and more generally extracellular vesicles (EVs), are now recognized as vectors of biological material with a role in intercellular communication. The building of knowledge on the subject has not only highlighted their role in certain pathologies, but also revealed their potential as biomarkers and therapeutic tools.
analyse marché, anticorps bispécifiques, MabDesign

Bispecific antibodies

This month's MabDesign market analysis gives you an overview of market dynamics and development projects targeting melanoma treatment.
market analysis , mabdesign, melanoma, cancer, oncology, pipeline

Melanoma

This month's MabDesign market analysis gives you an overview of market dynamics and development projects targeting melanoma treatment.
thérapie cellulaire, thérapie génique, marché, pipeline, ICGT

Cell and gene therapies

The first edition of our Innovations for Cell and Gene Therapies (ICGT) congress, organized in collaboration with the Société Française de Thérapie Cellulaire et génique (SFTCG), will take place on May 22, 2024, in Paris. In the meantime, this month we share an overview of the cell and gene therapy market.
téhrapie génique et cellulaire ; CAR-T ; MTIs ; médicaments thérapie innovante

Advanced therapy medicinal products: from the lab to the patient’s bed

Advanced therapy medicinal products (ATMPs) explore new therapeutic approaches based on genome modification, manipulation of patient or healthy donor cells and other innovative methods, representing a major transition from traditional medicine to more personalized and targeted medicine.
histoire des biomédicaments, biothérapies

The history of biologics: from discovery to therapeutic revolution

Biopharmaceuticals, or biotherapies, are becoming increasingly important on the market, and offer immense hope for the treatment of many diseases. From the first discoveries of vaccines to the recent development of cell and gene therapies and regenerative medicine, looking back at biologics' history lets us have a better understanding of the revolution that they provoked in the pharmaceutical industry and in modern medicine .

Jean-Roch Fabreguettes

MEARY

Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris

Jean-Roch Fabreguettes est un spécialiste de la recherche translationnelle et des phases précoces de développement clinique des médicaments de thérapie innovantes (MTI). Pharmacien, titulaire d’un doctorat de l’Université de Montpellier 1, il a travaillé plus de 25 ans dans le domaine et a contribué, pour des équipes académiques comme pour des start-ups, à la réalisation de plus de 30 programmes de recherche sur différents types de MTI : thérapie génique in vivo ou ex vivo, thérapie cellulaire, ingénierie tissulaire… Il est actuellement Directeur Médical et Personne Responsable du Centre MEARY de thérapie cellulaire et génique au sein de l’hôpital Saint-Louis à Paris. Le centre MEARY est une plateforme de l’Assistance Publique – Hôpitaux de Paris (AP-HP), dédiée à la fabrication de médicament de thérapie innovante expérimentaux. Laboratoire membre de l’ISCT, il est autorisé par l’ANSM et dispose d’un certificat GMP. A ce titre Jean-Roch Fabreguettes est impliqué dans le développement clinique et la fabrication de nombreux MTI : CAR-T cells, lymphocytes T régulateurs, cellules stromales mésenchymateuses…

Précédemment, Jean-Roch Fabreguettes a été expert Qualité (CMC) auprès de l’ANSM durant 9 ans et a conseillé différentes sociétés de biotechnologies. Il est un intervenant régulier pour l’Université Paris Cité et un membre actif de l’ISCT et de réseaux nationaux et internationaux sur les MTI (UNI-TC, Join4ATMP).